[Form 4] Day One Biopharmaceuticals, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Day One Biopharmaceuticals (DAWN) director filed a Form 4 reporting an option repricing approved on Oct 7, 2025 and effective Nov 6, 2025. The exercise price for certain fully vested stock options was reset to $8.99, the Nasdaq closing price on the effective date.
The repriced grants cover 48,072 options (from $24.65; expiring Aug 15, 2031), 28,700 (from $16.29; expiring Jun 20, 2032), 37,500 (from $12.69; expiring Jun 21, 2033), and 32,335 (from $13.87; expiring May 22, 2034). All other terms remain unchanged.
Exercising at the new price requires service through the Retention Period, which runs from Nov 6, 2025 until the earlier of the 12-month anniversary or a Corporate Transaction, with specified exceptions for death or Disability.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Garland J. Scott
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (right to buy Common Stock) | 48,072 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy Common Stock) | 48,072 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 28,700 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy Common Stock) | 28,700 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 37,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy Common Stock) | 37,500 | $0.00 | -- |
| Disposition | Stock Option (right to buy Common Stock) | 32,335 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy Common Stock) | 32,335 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 0 shares (Direct)
Footnotes (1)
- On October 7, 2025, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced on November 6, 2025 (the "Effective Date") with a new exercise price of $8.99 (if lower than the original exercise price), the closing price on Nasdaq as of the Effective Date. In order to exercise the repriced options at the new exercise price, the Reporting Person is required to remain in service with the Issuer through the Retention Period; provided that the additional premium payment will not be required if the Reporting Person's service to the Issuer is terminated by reason of death or Disability (as defined in the Company's 2021 Equity Incentive Plan ("the Plan")). (Continued from Footnote 1) The "Retention Period" commenced on the Effective Date and ends upon the earliest of (i) the 12-month anniversary of the Effective Date and (ii) a Corporate Transaction (as defined in the Plan). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. The options are fully vested.
